Literature DB >> 1601756

Lack of interaction between cefpirome and alcohol.

H B Lassman1, J W Hubbard, B L Chen, S K Puri.   

Abstract

An observer-blind randomized, placebo-controlled, crossover study was conducted in 22 healthy male subjects. They received 2 g cefpirome or placebo intravenously following an overnight fast. One hour later they consumed a single 0.5 g/kg dose of alcohol. The treatments were reversed after a seven-day 'washout' period. Subjects were evaluated for any adverse events or 'disulfiram-like' symptoms. The effects of cefpirome on the pharmacokinetics of alcohol were also studied. There were no statistically significant differences in mean values for the various pharmacokinetic parameters for plasma alcohol between the cefpirome and placebo treatment groups. There were no side effects or 'disulfiram-like' reactions following consumption of alcohol in either group. A single iv dose of 2 g cefpirome was well-tolerated in healthy males and, moreover, pre-treatment with cefpirome did not adversely affect the metabolism of alcohol in these subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601756     DOI: 10.1093/jac/29.suppl_a.47

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions between alcohol and other drugs.

Authors:  A G Fraser
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 3.  A review of the adverse events profile of cefpirome.

Authors:  E Rubinstein; R Labs; A Reeves
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 4.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.